C
Claudia Baratè
Researcher at University of Pisa
Publications - 84
Citations - 1443
Claudia Baratè is an academic researcher from University of Pisa. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 18, co-authored 72 publications receiving 1085 citations. Previous affiliations of Claudia Baratè include University of Perugia.
Papers
More filters
Journal ArticleDOI
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace,Michele Baccarani,Massimo Breccia,Giuliana Alimena,Gianantonio Rosti,Francesco Cottone,Giorgio Lambertenghi Deliliers,Claudia Baratè,Antonella Russo Rossi,Giuseppe Fioritoni,Luigia Luciano,Diamante Turri,Bruno Martino,Francesco Di Raimondo,Melissa Dabusti,Micaela Bergamaschi,Pietro Leoni,Maria Pina Simula,Luciano Levato,Stefano Ulisciani,Dino Veneri,Simona Sica,Alessandro Rambaldi,Marco Vignetti,Franco Mandelli +24 more
TL;DR: The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.
Journal ArticleDOI
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.
TL;DR: An overview of published evidence is provided addressing the key question of the mechanisms underlying ruxolitinib-induced immunosuppression of myeloproliferative neoplasms.
Journal ArticleDOI
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
F. Efficace,Michele Baccarani,Massimo Breccia,Francesco Cottone,Giuliana Alimena,Giorgio Lambertenghi Deliliers,Claudia Baratè,Giorgina Specchia,R. Di Lorenzo,Luigiana Luciano,Diamante Turri,Bruno Martino,Fabio Stagno,Melissa Dabusti,M. Bergamaschi,P. Leoni,Maria Pina Simula,Luciano Levato,Carmen Fava,Dino Veneri,Simona Sica,Alessandro Rambaldi,Giovanni Rosti,Marco Vignetti,Franco Mandelli +24 more
TL;DR: Health-related quality of life (HRQOL) is an important goal of therapy for chronic myeloid leukemia patients treated with current molecular-targeted therapies and chronic fatigue is the major factor limiting HRQOL of CML patients receiving imatinib.
Journal ArticleDOI
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia,Anna Sicuranza,Elisabetta Abruzzese,Alessandra Iurlo,Santina Sirianni,Antonella Gozzini,Sara Galimberti,Lara Aprile,Bruno Martino,Patrizia Pregno,Federica Sorà,Giulia Alunni,Carmen Fava,Fausto Castagnetti,Luca Puccetti,Massimo Breccia,Daniele Cattaneo,Marzia Defina,Olga Mulas,Claudia Baratè,Giovanni Caocci,Simona Sica,Alessandro Gozzetti,Luigiana Luciano,Monica Crugnola,Mario Annunziata,Mario Tiribelli,Paola Pacelli,Ilaria Ferrigno,Emilio Usala,Nicola Sgherza,Gianantonio Rosti,Alberto Bosi,Donatella Raspadori +33 more
TL;DR: This cross-sectional study provides the first evidence that “circulating” CML LSCs persist in the majority of CML patients in molecular response while on TKI treatment and even after TKI discontinuation.
Journal ArticleDOI
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
Simona Soverini,Luana Bavaro,Caterina De Benedittis,Margherita Martelli,Alessandra Iurlo,Nicola Orofino,Simona Sica,Federica Sorà,Francesca Lunghi,Fabio Ciceri,Sara Galimberti,Claudia Baratè,Massimiliano Bonifacio,Luigi Scaffidi,Fausto Castagnetti,Gabriele Gugliotta,Francesco Albano,Antonella Russo Rossi,Fabio Stagno,Francesco Di Raimondo,Mariella D'Adda,Eros Di Bona,Elisabetta Abruzzese,Gianni Binotto,Rosaria Sancetta,Marzia Salvucci,Isabella Capodanno,Mariella Girasoli,Sabrina Coluzzi,Immacolata Attolico,Caterina Musolino,Elisabetta Calistri,Mario Annunziata,Monica Bocchia,Stefania Stella,Anna Serra,Santa Errichiello,Giuseppe Saglio,Fabrizio Pane,Paolo Vigneri,Flavio Mignone,Maria Antonella Laginestra,Stefano Pileri,Antonio Percesepe,Elena Tenti,Gianantonio Rosti,Michele Baccarani,Michele Cavo,Giovanni Martinelli +48 more
TL;DR: The NEXT-in-CML study provides for the first time robust demonstration of the clinical relevance of low level mutations, supporting the incorporation of NGS-based BCR-ABL1 KD mutation screening results in the clinical decision algorithms.